menu
    • menu
    [{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Betaine-homocysteine S-methyltransferase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ SeegPharm"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Docosanol","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosette Pharma \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Palatin Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Palatin Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Palatin Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.42999999999999999,"dosageForm":"Insert","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Endoceutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Griseofulvin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"||Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosette Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Cosette Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Cosette Pharma

    Menu

    Cosette Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Mi...

                            Details : Bremelanotide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Mayne Pharma

                            Deal Size : $430.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Acquires Mayne Pharma for Women’s Health Leadership

                            Details : Through the acquisition, Cosette will utilize market-leading commercial products focused on women’s health, including Annovera (segesterone acetate & ethinyl estradiol) to prevent preganancy.

                            Product Name : Annovera

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Mayne Pharma

                            Deal Size : $430.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosette Acquires Ambien® and Ambien CR® from Sanofi US

                            Details : Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

                            Product Name : Ambien

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 10, 2024

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitroglycerin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Announces Approval and Launch Of First Generic Rectiv®

                            Details : Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.

                            Product Name : Rectiv-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2024

                            Lead Product(s) : Nitroglycerin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Acquires Vyleesi® from Palatin Technologies

                            Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.

                            Product Name : Vyleesi

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $12.0 million

                            January 03, 2024

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

                            Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.

                            Product Name : Vyleesi

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $12.0 million

                            January 02, 2024

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

                            Details : Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorde...

                            Product Name : Vyleesi

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $12.0 million

                            December 20, 2023

                            Lead Product(s) : Bremelanotide Acetate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Palatin Technologies

                            Deal Size : $171.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%

                            Details : Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.

                            Product Name : Dapsone

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 27, 2023

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : SeegPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%

                            Details : Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.

                            Product Name : Aczone-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 13, 2023

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : SeegPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prasterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Endoceutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.

                            Details : The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-t...

                            Product Name : Intrarosa

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            June 08, 2023

                            Lead Product(s) : Prasterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Endoceutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth